In this regard, checkpoint inhibitors such as anti-PD-1/PDL-1 antibodies have been used to restore immune control of tumors by disrupting co-inhibitory receptors and enhancing anti-tumor T cell responses. Here, PDCD1 is linked to neoplasm.